ID   HHUA
AC   CVCL_3866
SY   HHUA-1
DR   CLO; CLO_0050885
DR   BioSample; SAMN03472264
DR   cancercelllines; CVCL_3866
DR   Cosmic; 713497
DR   Cosmic; 735333
DR   Cosmic; 1177619
DR   Cosmic; 1223488
DR   Cosmic; 1241346
DR   Cosmic; 1622898
DR   Cosmic; 1696758
DR   Cosmic; 2030474
DR   DepMap; ACH-002026
DR   IARC_TP53; 2377
DR   RCB; RCB0658
DR   TOKU-E; 4122
DR   Wikidata; Q54887500
RX   PubMed=2429643;
RX   PubMed=2448191;
RX   PubMed=6532401;
RX   PubMed=6706228;
RX   PubMed=8105795;
RX   PubMed=9436037;
RX   PubMed=9573483;
RX   PubMed=10457904;
RX   PubMed=15901131;
WW   Info; ICLAC; -; https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
WW   Info; RCB; -; https://cell.brc.riken.jp/en/wp-content/uploads/pdf/announcement/RCB0658_en.pdf
CC   Problematic cell line: Possibly contaminated. HHUA (distributed by RCB) and SNG-M (distributed by JCRB) share similar STR profiles and have been established by the same research group. While HHUA was described in 1984 and SNG-M in 1977 it has not been possible to establish which of the two cell lines are derived from each other. Thus it has been decided to consider them as being sister cell lines originating from the same donor.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00628.
CC   Population: Japanese.
CC   Doubling time: 34 hours (Note=At 5th passage), 30 hours (Note=At 15th passage) (PubMed=6706228); 30 hours (PubMed=6532401); 28 hours (PubMed=10457904).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ala138Val (c.413C>T); ClinVar=VCV000184863; Zygosity=Unspecified (PubMed=8105795).
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
ST   Source(s): DepMap=ACH-002026; RCB=RCB0658
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 8,11
ST   D16S539: 10,12
ST   D18S51: 12,18,19
ST   D21S11: 29,30
ST   D3S1358: 14,15
ST   D5S818: 9,12,13,14 (DepMap=ACH-002026)
ST   D5S818: 9,13,14 (RCB=RCB0658)
ST   D7S820: 10,13 (RCB=RCB0658)
ST   D7S820: 10,13,14 (DepMap=ACH-002026)
ST   D8S1179: 11,13
ST   FGA: 21,22
ST   Penta D: 8,11
ST   Penta E: 11,13
ST   TH01: 6,7
ST   TPOX: 8,9
ST   vWA: 17,18,19 (RCB=RCB0658)
ST   vWA: 17,19,20,21 (DepMap=ACH-002026)
DI   NCIt; C7359; Endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1707 ! SNG-M
OI   CVCL_S914 ! SNG-P
SX   Female
AG   52-54Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 27
//
RX   PubMed=2429643; DOI=10.1111/j.1447-0756.1986.tb00192.x;
RA   Ishiwata, Isamu
RA   Ishiwata, Chieko
RA   Nozawa, Shiro
RA   Ishikawa, Hiroshi
RT   "CA125 production by gynecologic tumors in vitro and its modulation
RT   induced by dibutyl cyclic adenosine monophosphate.";
RL   Asia Oceania J. Obstet. Gynaecol. 12:285-290(1986).
//
RX   PubMed=2448191; DOI=10.1016/0090-8258(88)90151-5;
RA   Ishiwata, Isamu
RA   Ishiwata, Chieko
RA   Soma, Masayuki
RA   Ono, Isao
RA   Nakaguchi, Takenori
RA   Ishikawa, Hiroshi
RT   "Tumor angiogenic activity of gynecologic tumor cell lines on the
RT   chorioallantoic membrane.";
RL   Gynecol. Oncol. 29:87-93(1988).
//
RX   PubMed=6532401; DOI=10.1111/j.1447-0756.1984.tb00721.x;
RA   Ishiwata, Isamu
RA   Ishiwata, Chieko
RA   Ishikawa, Hiroshi
RT   "Effects of estradiol-17 beta and progesterone on cell proliferation
RT   and differentiation of the human endometrial carcinoma cell line
RT   (HHUA) in vitro.";
RL   Asia Oceania J. Obstet. Gynaecol. 10:531-538(1984).
//
RX   PubMed=6706228; DOI=10.1016/0090-8258(84)90212-9;
RA   Ishiwata, Isamu
RA   Ishiwata, Chieko
RA   Soma, Masayuki
RA   Arai, Junichiro
RA   Ishikawa, Hiroshi
RT   "Establishment of human endometrial adenocarcinoma cell line
RT   containing estradiol-17 beta and progesterone receptors.";
RL   Gynecol. Oncol. 17:281-290(1984).
//
RX   PubMed=8105795; DOI=10.1002/mc.2940080303;
RA   Enomoto, Takayuki
RA   Fujita, Masami
RA   Inoue, Masaki
RA   Nakazawa-Miyamoto, Aiko
RA   Tanizawa, Osamu
RA   Nomura, Taisei
RT   "Alterations of the Rb gene and its association with Ki-ras activation
RT   and p53 inactivation in endometrial adenocarcinoma.";
RL   Mol. Carcinog. 8:132-137(1993).
//
RX   PubMed=9436037;
RA   Soma, Masayuki
RA   Ishiwata, Isamu
RA   Ishiwata, Chieko
RA   Nakaguchi, Takenori
RA   Ono, Isao
RA   Kiguchi, Kazushige
RA   Hashimoto, Hisashi
RA   Tachibana, Toshiaki
RA   Ishikawa, Hiroshi
RA   Nozawa, Shiro
RT   "Tissue reconstruction of gynecologic tumor cells in the rotation
RT   culture system.";
RL   Hum. Cell 10:175-181(1997).
//
RX   PubMed=9573483;
RA   Ishiwata, Isamu
RA   Tokieda, Yuko
RA   Ishiwata, Chieko
RA   Okane, Natsumi
RA   Iguchi, Megumi
RA   Sato, Kahei
RA   Ishikawa, Hiroshi
RT   "Effects of feeder cells (human cancer cell lines) on the development
RT   of mouse embryos by co-culture.";
RL   Hum. Cell 10:237-246(1997).
//
RX   PubMed=10457904;
RA   Ishiwata, Isamu
RA   Sudo, Tadashi
RA   Kiguchi, Kazushige
RA   Ishikawa, Hiroshi
RT   "Tumor angiogenesis factors produced by cancer cells.";
RL   Hum. Cell 12:37-46(1999).
//
RX   PubMed=15901131; DOI=10.1016/j.prp.2005.01.002;
RA   Murai, Yoshihiro
RA   Hayashi, Shinichi
RA   Takahashi, Hiroyuki
RA   Tsuneyama, Koichi
RA   Takano, Yasuo
RT   "Correlation between DNA alterations and p53 and p16 protein
RT   expression in cancer cell lines.";
RL   Pathol. Res. Pract. 201:109-115(2005).
//